MORGAN STANLEY PLC/CALL/MEDTRONIC/90/0.1/20.12.24 Stock

Warrant

DE000MB8M3T9

Market Closed - Börse Stuttgart 02:47:38 2024-07-11 pm EDT
0.122 EUR +16.19% Intraday chart for MORGAN STANLEY PLC/CALL/MEDTRONIC/90/0.1/20.12.24
Current month-3.17%
1 month-44.80%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-11 0.122 +16.19%
24-07-10 0.105 +0.96%
24-07-09 0.104 -3.70%
24-07-08 0.108 -10.74%
24-07-05 0.121 +12.04%

Delayed Quote Börse Stuttgart

Last update July 11, 2024 at 02:47 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer Morgan Stanley
WKN MB8M3T
ISINDE000MB8M3T9
Date issued 2023-07-12
Strike 90 $
Maturity 2024-12-20 (162 Days)
Parity 10 : 1
Emission price 0.96
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.05
Lowest since issue 0.104
Spread 0.002
Spread %1.60%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
78.07 USD
Average target price
93.63 USD
Spread / Average Target
+19.93%
Consensus